Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma

Published:2005-06-10 Issue:5 Volume:56 Page:510-520
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Zagon Ian S.,Jaglowski Jeffrey R.,Verderame Michael F.,Smith Jill P.,Leure-duPree Alphonse E.,McLaughlin Patricia J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-005-1028-x.pdf

Reference48 articles.

1. Jemal A, Murray T, Ward E, Samuels A., Twari RC, Ghafoor A., Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

2. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49:33–64

3. Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Eng J Med 326:455–465

4. Akerele CE, Rybalova I, Kaufman HL, Mani S (2003) Current approaches to novel therapeutics in pancreatic cancer. Invest New Drugs 21:113–129

5. Li D, Xie K, Wolff R, Abbruzzese (2004) Pancreatic cancer. Lancet 363:1049–1057

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma;Pharmaceutics;2024-02-16

2. Role of Opioid Growth Factor-Opioid Growth Factor Receptor (OGF-OGFr) Axis in Cancer Management;J BIOL REG HOMEOS AG;2024

3. The Opioid Growth Factor in Growth Regulation and Immune Responses in Cancer;Advances in Neurobiology;2024

4. Research progress of opioid growth factor in immune-related diseases and cancer diseases;International Immunopharmacology;2021-10

5. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy;International Immunopharmacology;2021-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3